STAT3 and hepatocellular carcinoma: In the docking model, it binds with SH2-domain of STAT3 and prevents STAT3 phosphorylation at Tyr705, leading to inhibition of downstream STAT3 activities and apoptosis in multiple cancer cell lines including breast, pancreatic, hepatocellular carcinoma and rhabdomyosarcoma (IC50 ≈ 15-50 μM) [29-31].